NCT00306748已完成2 期
A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug, 300 ug, 1000 ug, or Placebo to Patients With Chronic Constipation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 28
- 主要终点
- Safety will be evaluated on an ongoing basis by completing physical examinations, ECGs, clinical laboratory tests, and adverse event reporting.
研究概览
简要总结
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-breastfeeding female, age 18-70 years old at the time of first dose;
- •Sexually active patients of childbearing potential agree to use double-barrier birth control;
- •Females of childbearing potential must complete negative pregnancy tests prior to first dose;
- •Negative colonoscopy within 10 years or completion of negative flexible sigmoidoscopy if under the age of 50 provided there is no history of rectal bleeding, weight loss, or anemia;
- •BMI must be greater than/equal to 18.5 and less than 35.0;
- •Successful completion of physical exam, 12-lead ECG, clinical laboratory tests prior to first dose of study medication;
- •Vital signs must not have clinically-significant findings within 4 hours of first dose of study medication;
- •Patient reports 3 or less spontaneous bowel movements (SBMs) per week and meets 1 or more of the following criteria for constipation for 12 weeks in the previous 12 months: straining at least 25% bowel movements (BMs), lumpy or hard stools at least 25% of BMs, or sensation of incomplete evacuation at least 25% of BMs;
- •Patient reports 3 or less SBMs during the 7-day Pre-treatment Period;
- •Patient is compliant with IVRS for at least 6 days in the 7-day Pre-treatment Period.
排除标准
- •Use of investigational drug within 30 days;
- •Laxative/enema-induced diarrhea within 60 days;
- •Patient meets ROME II criteria for functional diarrhea;
- •Most bothersome symptom is moderate or severe abdominal pain or abdominal discomfort;
- •History of cancer, inflammatory bowel disease, ischemic colitis, bowel resection, colostomy, or fecal impaction;
- •Diagnosis of cathartic colon or laxative/enema abuse, pelvic floor dysfunction, evacuation disorder, bulimia, anorexia, or neurological disorders;
- •Surgery within 30 days or GI surgery within 6 months of first dose of study medication. Cholecystectomy and/or appendectomy are acceptable if completed more than 60 days prior to first dose of study medication;
- •Patient may not use any disallowed medications (prescription and/or over-the-counter treatments for chronic constipation or C-IBS, drugs that target 5-HT4, 5-HT2b, or 5-HT3 receptors, narcotics, anti-cholinergic agents, GI preparations, etc.) during the 7-day Pre-treatment Period or during the study. Stable, continuous (30 days or more) use of dietary fiber is acceptable.
- •Any acute or chronic condition that would limit the patient's ability to complete and/or participate in the study.
结局指标
主要结局
Safety will be evaluated on an ongoing basis by completing physical examinations, ECGs, clinical laboratory tests, and adverse event reporting.
次要结局
- Stool Frequency will be reported daily
- Stool Consistency (Bristol Stool Form Scale) will be reported daily
- Stool Ease of Passage will be reported daily
- Stool Completeness of Evacuation will be reported daily
- Patient Assessment of Abdominal Discomfort will be reported weekly
- Patient Assessment of Constipation will be reported weekly
- Patient Assessment of Overall Relief will be reported weekly
- Part 1 of the Irritable Bowel Symptom Severity Scale (IBSSS) will be reported once pre-dose and once post-dose.
研究者
研究点 (28)
Loading locations...
相似试验
已完成
3 期
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)OsteoarthritisNCT00092703Organon and Co6,000
已完成
2 期
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With GastroparesisGastroparesisNCT00861809GlaxoSmithKline11
已完成
1 期
Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and NaproxenHealthyNCT00366262Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female ParticipantsHealthyNCT04185051Janssen Research & Development, LLC76
已完成
1 期
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy SubjectsGastric UlcerNCT03291418Antibe Therapeutics Inc.258